PremiumThe FlyEvoke Pharma to present new data comparing TD receiving OCMP treatment Evoke Pharma’s Earnings Call Highlights Revenue Growth and Strategic Partnerships Evoke Pharma Reports Strong Revenue Growth in 2024 PremiumThe FlyEvoke receives notice of allowance for two additional patent applications Evoke Pharma Reports Q3 2024 Financial Results Is EVOK a Buy, Before Earnings? PremiumThe FlyEvoke Pharma announces warrant proceeds, board expansion Evoke Pharma files $50M mixed securities shelf Evoke Pharma trading resumes